Cargando…
(68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study
(68)Ga-labeled fibroblast activation protein inhibitor ((68)Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUV(max) and tumor-to-background ratio (TBR) in breast cancer (BC) patients than (18)F-FDG PET/CT. Here, we aimed to evaluate the suitability of (68)Ga-FAPI PET/CT f...
Autores principales: | Chen, Ling, Zheng, Shan, Chen, Linying, Xu, Sunwang, Wu, Kunlin, Kong, Lingjun, Xue, Jiajie, Chen, Xiangjin, Miao, Weibing, Zhu, Youzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society of Nuclear Medicine
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690122/ https://www.ncbi.nlm.nih.gov/pubmed/37918866 http://dx.doi.org/10.2967/jnumed.123.266079 |
Ejemplares similares
-
SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
por: Zhu, Youzhi, et al.
Publicado: (2023) -
Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020) -
Localization of Pyelonephritis by (68)Ga-FAPI PET CT
por: Jagtap, Rajlaxmi Rangrao, et al.
Publicado: (2023) -
Musculoskeletal pitfalls in (68)Ga-PSMA
PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023) -
Diagnostic challenges in a patient with an occult insulinoma:(68 )Ga‐DOTA‐exendin‐4 PET/CT and (68)Ga‐DOTATATE PET/CT
por: Bongetti, Elisa, et al.
Publicado: (2018)